Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target

Abstract

This is the first study to report IDO2 expression in PDA and related cancers indicating that IDO2 genetic polymorphisms do not negate interferon-gamma-inducible protein expression. Taken together, our data strongly suggest that the clinical lead compound d-1-methyl-tryptophan might be useful in treatment of PDA.